These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10025839)

  • 21. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice.
    Deshpande SV; DeNardo SJ; Meares CF; McCall MJ; Adams GP; Moi MK; DeNardo GL
    J Nucl Med; 1988 Feb; 29(2):217-25. PubMed ID: 3258025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.
    Kukis DL; DeNardo GL; DeNardo SJ; Mirick GR; Miers LA; Greiner DP; Meares CF
    Cancer Res; 1995 Feb; 55(4):878-84. PubMed ID: 7850803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.
    O'Donnell RT; Leigh BR; Christensen SD; Goldstein DS; Kukis DL; Shen S; Yuan A; DeNardo DA; Kroger LA; DeNardo GL
    Cancer Biother Radiopharm; 1999 Jun; 14(3):167-76. PubMed ID: 10850301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Milestones in the development of Lym-1 therapy.
    DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ
    Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
    Schillaci O; DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; O'Donnell RT; Lamborn KR
    Cancer Biother Radiopharm; 2007 Aug; 22(4):521-30. PubMed ID: 17803447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Copper-67 as a therapeutic nuclide for radioimmunotherapy.
    Novak-Hofer I; Schubiger PA
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):821-30. PubMed ID: 12029558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates.
    Kukis DL; Diril H; Greiner DP; DeNardo SJ; DeNardo GL; Salako QA; Meares CF
    Cancer; 1994 Feb; 73(3 Suppl):779-86. PubMed ID: 8306260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors.
    Delaloye AB; Delaloye B; Buchegger F; Vogel CA; Gillet M; Mach JP; Smith A; Schubiger PA
    J Nucl Med; 1997 Jun; 38(6):847-53. PubMed ID: 9189128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
    Shen S; DeNardo GL; Yuan A; Hartmann-Siantar C; O'Donnell RT; DeNardo SJ
    Cancer Biother Radiopharm; 2005 Dec; 20(6):662-70. PubMed ID: 16398618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
    Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
    J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.
    DeNardo GL; DeNardo SJ; Macey DJ; Shen S; Kroger LA
    Cancer; 1994 Feb; 73(3 Suppl):1038-48. PubMed ID: 8306246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
    DeNardo GL; DeNardo SJ; Lamborn KR; Goldstein DS; Levy NB; Lewis JP; O'Grady LF; Raventos A; Kroger LA; Macey DJ; McGahan JP; Mills SL; Shen S
    Cancer Biother Radiopharm; 1998 Aug; 13(4):239-54. PubMed ID: 10850360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy.
    Shen S; DeNardo GL; Jones TD; Wilder RB; O'Donnell RT; DeNardo SJ
    J Nucl Med; 1998 Jul; 39(7):1223-9. PubMed ID: 9669399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.
    Scheinberg DA; Straus DJ; Yeh SD; Divgi C; Garin-Chesa P; Graham M; Pentlow K; Coit D; Oettgen HF; Old LJ
    J Clin Oncol; 1990 May; 8(5):792-803. PubMed ID: 2332769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strategies for enhancement of radioimmunotherapy.
    DeNardo G; DeNardo S; Kukis D; Diril H; Suey C; Meares C
    Int J Rad Appl Instrum B; 1991; 18(6):633-40. PubMed ID: 1743986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations.
    Salako QA; O'Donnell RT; DeNardo SJ
    J Nucl Med; 1998 Apr; 39(4):667-70. PubMed ID: 9544679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
    Juweid M; Sharkey RM; Siegel JA; Behr T; Goldenberg DM
    Cancer Res; 1995 Dec; 55(23 Suppl):5827s-5831s. PubMed ID: 7493354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
    Siegel JA; Kroll S; Regan D; Kaminski MS; Wahl RL
    J Nucl Med; 2002 Mar; 43(3):354-63. PubMed ID: 11884495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.